Search Results for: cronos
Aurora and 22nd Century Group License Foundational Biosynthesis IP to Cronos Group
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) (“Aurora”), the Canadian company defining the future of cannabinoids worldwide,…
Aurora and 22nd Century Group License Foundational Biosynthesis IP to Cronos Group
Aurora Cannabis Inc. (NASDAQ | TSX: ACB) (“Aurora”), the Canadian company defining the future of…
Cronos Group Provides Bi-Weekly MCTO Status Update and Announces Receipt of Nasdaq Listing Delinquency Letter
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) is providing a…
Cronos Group Files Form 12b-25
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) today announced that…
Cronos Group Chief Innovation Officer Dr. Todd Abraham to Retire
Arye Weigensberg Named Interim Head of Research and Development Search to Identify Permanent Successor Well…
Cronos Group and Ginkgo Bioworks Announce Achievement of Equity Milestone in Partnership to Produce Cultured Cannabinoids
Cronos Group, Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group”), an innovative global cannabinoid company, and Ginkgo Bioworks (“Ginkgo”),…
Cronos Group Inc. to Speak at the Canaccord Genuity 41st Annual Growth Conference
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global…
Cronos Group Reports 2021 Second Quarter Results
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), today announces its 2021…
Cronos Group Launches Delicious New Dual-Flavor Cannabis Gummies
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), announces the launch…
Cronos Group Inc. to Hold 2021 Second Quarter Earnings Conference Call on August 6, 2021
Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) will hold its…
Recent Comments